Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer | NCT07747740

NCT07747740

Overview

NCT ID: NCT07747740
Lead Sponsor: Blokhin's Russian Cancer Research CenterOTHER
Official Title: A Prospective, Randomized, Open-Label, Phase II Trial Comparing Sequential Intravesical Gemcitabine Plus Docetaxel With Sequential Intravesical Gemcitabine Plus Mitomycin C in Patients With BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
Brief Summary: This prospective, randomized, open-label, phase II clinical trial compares two sequential intravesical chemotherapy regimens in patients with bacillus Calmette-Guérin (BCG)-unresponsive high-grade non-muscle-invasive bladder cancer (NMIBC) following complete transurethral resection of bladder tumor (TURBT). Participants are randomized in a 1:1 ratio to receive sequential intravesical gemcitabine plus docetaxel or sequential intravesical gemcitabine plus mitomycin C. The primary objective is to compare 12-month event-free survival between treatment groups. Secondary objectives include evaluation of cystectomy-free survival, progression-free survival, treatment safety, tolerability, and patient-reported quality of life.
Conditions

Status and Timeline

Status: Recruiting
Last Update Posted: Aug 5, 2026Actual
Start Date: Jul 9, 2026Actual
Primary Completion Date: Dec 30, 2029Estimated
Completion Date

Participation Criteria

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: No
Eligibility Criteria: Inclusion Criteria:

Age ≥18 years.

Histologically confirmed BCG-unresponsive non-muscle-invasive urothelial bladder cancer (NMIBC).

Complete transurethral resection of bladder tumor (TURBT) before study treatment.

Intermediate- or high-risk NMIBC according to current clinical guidelines.

Candidate for intravesical chemotherapy.

ECOG performance status 0-2.

Adequate hematologic, renal, and hepatic function.

Written informed consent.

Exclusion Criteria:

Muscle-invasive (≥T2), locally advanced, or metastatic urothelial carcinoma.

Upper urinary tract urothelial carcinoma requiring treatment.

Previous hypersensitivity to gemcitabine, docetaxel, mitomycin C, or formulation components.

Active uncontrolled urinary tract infection.

Pregnancy or breastfeeding.

Concurrent participation in another interventional clinical trial.

Any serious uncontrolled medical condition that, in the investigator's opinion, would interfere with study participation or interpretation of results.

Study Plan

Study Type: Interventional
Phase: Phase 2
Enrollment: 228Estimated
Primary Purpose: Treatment
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking

Contacts and Locations

Central Contacts: Nshan Sedrakyan, MDContact
nick977773@gmail.com

Similar Studies

Participant Group/Arms

Sequential Gemcitabine + DocetaxelExperimental

Participants receive sequential intravesical gemcitabine followed by docetaxel after complete TURBT. Treatment consists of six weekly induction instillations followed by monthly maintenance instillations for 12 months.

Drug: Gemcitabin

Drug: Docetaxel

Sequential Gemcitabine + Mitomycin CActive Comparator

Participants receive sequential intravesical gemcitabine followed by mitomycin C after complete TURBT. Treatment consists of six weekly induction instillations followed by monthly maintenance instillations for 12 months.

Drug: Gemcitabin

NCT07322263Recruiting

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

NCT04386746Active, not recruiting

Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer

NCT06388720Recruiting

The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

NCT05644041Active, not recruiting

Intravesical Gem/Doce in Patients With NMIBC

NCT06972615Recruiting

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

NCT05671900Unknown status

Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer

NCT04179162Active, not recruiting

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

NCT01442519Completed

Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer